Showing 1 – 20 of 664
Relevance | Newest | Oldest |
  • The Hunt Continues for Early Ovarian Cancer Clues

    Abstract Full Text
    JAMA. 2017; 318(1):14-16. doi: 10.1001/jama.2017.5545

    This Medical News article discusses efforts aimed at developing ovarian cancer screening and prevention strategies.

  • JAMA June 20, 2017

    Figure 2: Estimated Cumulative Risks of Breast and Ovarian Cancer in Mutation Carriers

    Kaplan-Meier estimates of cumulative risks of breast and ovarian cancers. In the breast cancer analysis, women were censored at risk-reducing bilateral mastectomy. In the ovarian cancer analysis, women were censored for risk-reducing salpingo-oophorectomy. Number at risk indicates the number of women who remained at risk at the end of the 10-year age category (eg, in panel A, there were 138 women with BRCA1 mutations still at risk of breast cancer at the end of the age 50-60 years period). The earliest follow-up started at age 18 years.
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

    Abstract Full Text
    JAMA. 2017; 317(23):2402-2416. doi: 10.1001/jama.2017.7112

    This cohort study estimates age-specific risks of breast, ovarian, and contralateral breast cancer among carriers of BRCA1 and BRCA2 mutations and evaluates risk modification by family cancer history and location of the mutation within the BRCA gene.

  • Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force

    Abstract Full Text
    free access
    JAMA. 2017; 317(9):954-966. doi: 10.1001/jama.2016.12819

    This Evidence Report to support the 2017 US Preventive Services Task Force Recommendation Statement on the screening pelvic examination summarizes current evidence on benefits, accuracy, and harms of periodic screening pelvic examination for gynecologic conditions in asymptomatic, nonpregnant women.

  • Ovarian Cancer Drug Approved

    Abstract Full Text
    JAMA. 2017; 317(5):466-466. doi: 10.1001/jama.2017.0026
  • Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine

    Abstract Full Text
    JAMA. 2016; 315(18):1943-1944. doi: 10.1001/jama.2016.2640

    This Viewpoint discusses a recent report from the National Academies of Sciences, Engineering, and Medicine that emphasizes the latest knowledge in ovarian cancer research and recommends approaches that will benefit outcomes for women with or at risk for ovarian cancer.

  • Familial Risk and Heritability of Cancer Among Twins in Nordic Countries

    Abstract Full Text
    free access is active quiz
    JAMA. 2016; 315(1):68-76. doi: 10.1001/jama.2015.17703

    This study estimates familial risk and heritability of cancer types in a large twin cohort using data from population-based registers in Denmark, Finland, Norway, and Sweden.

  • Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer

    Abstract Full Text
    free access is active quiz
    JAMA. 2015; 313(13):1347-1361. doi: 10.1001/jama.2014.5985

    This genetic epidemiology study reports that risk of breast and ovarian cancer among women with BRCA1 and BRCA2 mutations varies by mutation type and location.

  • JAMA April 7, 2015

    Figure 2: Hazard Ratio of Breast Cancer Relative to the Hazard Ratio of Ovarian Cancer by BRCA1 Nucleotide Position

    The graph shows the ratio of hazard ratios (blue data markers) and 95% CI (error bars) for the mutation bins defined across the span of the coding DNA sequence of the BRCA1 gene. Black arrowheads under the bins indicate 2 founder mutations of clinical interest in the Ashkenazi Jewish population. Regions inferred to be breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) are shown at the bottom. Solid light blue lines indicate regions found to be statistically significant; dashed light blue lines indicate regions in the same direction of effect that were not statistically significant. eTable 2 in the Supplement lists the bins and risks used to define the BCCRs and OCCRs.
  • JAMA April 7, 2015

    Figure 3: Hazard Ratio of Breast Cancer Relative to the Hazard Ratio of Ovarian Cancer by BRCA2 Nucleotide Position

    The graph shows the ratio of hazard ratios (blue data markers) and 95% CI (error bars) for the mutation bins defined across the span of the coding DNA sequence of the BRCA2 gene. The black arrowhead under the bins indicates a founder mutation of clinical interest in the Ashkenazi Jewish population. The regions inferred to be breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) are shown at the bottom; the solid light blue lines indicate regions found to be statistically significant. eTable 3 in the Supplement lists the bins and risks used to define to define the BCCRs and OCCRs.
  • Necrotic Black Eschars on the Lower Extremities in a 57-Year-Old Woman With Ovarian Cancer

    Abstract Full Text
    JAMA. 2013; 310(12):1281-1282. doi: 10.1001/jama.2013.277797
  • JAMA July 24, 2013

    Figure: Supreme Court Rules Against Gene Patents

    The discovery of the BRCA1 gene and its role in hereditary breast and ovarian cancers in the early 1990s by Mary-Claire King, PhD, of the University of Washington, sparked a race to isolate and patent BRCA1 and a related gene, BRCA2. But a recent Supreme Court decision invalidated such patents.
  • The Importance of Potential Studies That Have Not Existed and Registration of Observational Data Sets

    Abstract Full Text
    JAMA. 2012; 308(6):575-576. doi: 10.1001/jama.2012.8144
  • JAMA June 20, 2012

    Figure: Screening Women for Ovarian Cancer Still Does More Harm Than Good

    The US Preventive Services Task Force upheld its position that the most recent scientific evidence doesn't justify routinely screening asymptomatic women for ovarian cancer.
  • Screening Women for Ovarian Cancer Still Does More Harm Than Good

    Abstract Full Text
    JAMA. 2012; 307(23):2474-2475. doi: 10.1001/jama.2012.5646
  • Management of Ovarian Cancer: A 75-Year-Old Woman Who Has Completed Treatment

    Abstract Full Text
    is expired quiz
    JAMA. 2012; 307(13):1420-1429. doi: 10.1001/jama.2012.269
    Ms W, a 75-year-old woman, is in complete remission after surgery and postoperative chemotherapy for stage IIIC epithelial ovarian cancer. In this Clinical Crossroads article, Konstantinopoulos and Awtrey discuss the signs, symptoms, and risk factors for ovarian cancer; prognostic factors and surgical and postoperative medical management; and current recommendations for ovarian cancer screening and patient follow-up.
  • Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer

    Abstract Full Text
    JAMA. 2012; 307(4):408-410. doi: 10.1001/jama.2012.24
  • JAMA October 12, 2011

    Figure 1:BRCA1/2 Mutations in 316 Ovarian Cancer Cases

    BRCT indicates BRCA1 C-terminal domain; RING, RING-type zinc finger domain. Mutations are mapped to the corresponding exons of BRCA1 and BRCA2.
  • JAMA October 12, 2011

    Figure 4: Hypermethylation of BRCA1 Promoter in 316 Ovarian Cancer Cases

    A. The GC percentage (top panel), CpG islands, and 6 array probes were annotated to BRCA1 in an Illumina Infinium DNA methylation microarray (Illumina Inc, San Diego, California) and were visualized using the University of California Santa Cruz (UCSC) genome browser. The GC percentage track shows the percentage of G (guanine) and C (cytosine) bases in 5-base windows. Three other probes (see “Methods”) annotated to BRCA1 are not shown because they were too far away from the BRCA1 transcription start site. B, Heat map shows the DNA methylation of BRCA1 promoter across 316 cases. Four probes located in the promoter CpG island of BRCA1 are arranged in rows.
  • JAMA October 12, 2011

    Figure 5:BRCA1 mRNA Expression in 316 Ovarian Cancer Cases

    BRCA1 mRNA expression in different status groups. Each data point represents expression value of BRCA1 expression in 1 case. The top and bottom of the box indicate lower and upper quartiles; the solid line indicates the median; the whiskers indicate the most extreme data points within the 1.5 times of interquartile range from the box.